Dendritic cell vaccination in allogeneic stem cell recipients: Induction of human cytomegalovirus (HCMV)-specific cytotoxic T lymphocyte responses even in patients receiving a transplant from an HCMV-seronegative donor

Journal of Infectious Diseases

Volumn 196, Issue 5, 2007, Pages 699-704

  Grigoleit, Götz Ulrich ^a,c   Kapp, Markus ^a   Hebart, Holger ^b   Fick, Kerstin ^a   Beck, Robert ^b   Jahn, Gerhard ^b   Einsele, Hermann ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CORTICOSTEROID; DENDRITIC CELL VACCINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG EFFICACY; GRAFT VERSUS HOST REACTION; HIGH RISK POPULATION; HUMAN; HUMAN CYTOMEGALOVIRUS; IMMUNE DEFICIENCY; IMMUNOSTIMULATION; INFECTION; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN IRRITATION; VACCINATION;

CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DENDRITIC CELLS; HUMANS; STEM CELL TRANSPLANTATION; T-LYMPHOCYTES, CYTOTOXIC; VACCINATION; VIRAL PROTEINS; VIRAL VACCINES;

EID: 34548094872     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/520538     Document Type: Article

References (15)

1. Brossart P, Wirths S, Stuhler G, Reichardt VL, Kanz L, Brugger W. Induction of cytotoxic T-lymphocyte responses in vivo after vaccination with peptide-pulsed dendritic cells. Blood 2000; 96:3102-4.
2. Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD. Restoration of viral immunity in immunodeficient humans by adoptive transfer of T cell clones. Science 1992; 257:238-41.
3. Ljungman P, Reusser P, de la Camara R, et al. Management of CMV infections: recommendations from the infectious diseases working party of the EBMT. Bone Marrow Transplant 2004; 33:1075-81.
4. Lacey SF, Gallez-Hawkins G, Crooks M, et al. Characterization of cytotoxic function of CMV-pp65-specific CD8+ T-lymphocytes identified by HLA tetramers in recipients and donors of stem-cell transplants. Transplantation 2002; 74:722-32.
5. Peggs KS, Verfuerth S, Pizzey A, et al. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet 2003; 362:1375-7.
6. Einsele H, Roosnek E, Rufer N, et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 2002; 99:3916-22.
7. Bunde T, Kirchner A, Hoffmeister B, et al. Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells. J Exp Med 2005; 201:1031-6.
8. Cobbold M, Khan N, Pourgheysari B, et al. Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J Exp Med 2005; 202:379-86.
9. Boeckh M, Nichols WG. The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy. Blood 2004; 103:2003-8.
10. Ljungman P, Brand R, Einsele H, Frassoni F, Niederwieser D, Cordonnier C. Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megafile analysis. Blood 2003; 102:4255-60.
11. Einsele H, Bertz H, Beyer J, et al. Infectious complications after allogeneic stem cell transplantation: epidemiology and interventional therapy strategies - guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2003; 82:175-85.
12. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony stimulating factor plus interleukin 4 and down regulated by tumor necrosis factor alpha. J Exp Med 1994; 179:1109-18.
13. Hebart H, Daginik S, Stevanovic S, et al. Sensitive detection of human cytomegalovirus peptide-specific cytotoxic T-lymphocyte responses by interferon-gamma-enzyme-linked immunospot assay and flow cytometry in healthy individuals and in patients after allogeneic stem cell transplantation. Blood 2002; 99:3830-7.
14. Einsele H, Ehninger G, Hebart H, et al. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood 1995; 86:2815-20.
15. Hebart H, Muller C, Loffler J, Jahn G, Einsele H. Monitoring of CMV infection: a comparison of PCR from whole blood, plasma-PCR, pp65-antigenemia and virus culture in patients after bone marrow transplantation. Bone Marrow Transplant 1996; 17:861-8.